The Flagship train keeps chugging with its 'intersystems' player eyeing the clinic next year with 3 new drugs
Flagship companies like to move quickly these days. Just one day after Valo Health announced a move to Nasdaq via SPAC after its unveiling last September, another Flagship biotech is putting the finishing touches on a new fundraise.
Senda Biosciences closed their Series B on Thursday morning with $98 million in tow, the Cambridge, MA-based company said. The raise comes roughly seven and a half months since Flagship launched the biotech to explore what they call “intersystems biology,” or the connections between how humans coevolved with plants and bacteria.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 129,500+ biopharma pros reading Endpoints daily — and it's free.